Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 10/20 | 0.82 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.60 |
| ▸ | LMNA | P02545 | 1/20 | 0.57 |
| ▸ | POLB | P06746 | 1/20 | 0.55 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.55 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.54 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.54 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.54 |
| ▸ | TSHR | P16473 | 1/20 | 0.54 |
| ▸ | TAAR1 | Q96RJ0 | 2/20 | 0.53 |
| ▸ | SLC18A2 | Q05940 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8092729 | 1.00 | SIGMAR1 (0.82) | SIGMAR1SMN1; SMN2LMNAPOLBMAPK1 | |
| N-Benzylamphetamine SCHEMBL2795222 | 0.91 | SIGMAR1 (1.00) | SIGMAR1LMNAPOLBMAPK1CYP1A2 | |
| N-Benzylamphetamine SCHEMBL2451256 | 0.91 | SIGMAR1 (1.00) | SIGMAR1LMNAPOLBMAPK1CYP1A2 | |
| N-Benzylamphetamine SCHEMBL2798189 | 0.91 | SIGMAR1 (1.00) | SIGMAR1LMNAPOLBMAPK1CYP1A2 | |
| N-Benzylamphetamine SCHEMBL8085021 | 0.89 | SIGMAR1 (0.96) | SIGMAR1LMNAPOLBMAPK1CYP1A2 | |
| SCHEMBL606189 | 0.87 | SIGMAR1 (0.85) | SIGMAR1LMNAPOLBMAPK1CYP1A2 | |
| SCHEMBL24997843 | 0.84 | SIGMAR1 (0.79) | SIGMAR1LMNAPOLBMAPK1CYP1A2 | |
| SCHEMBL8091283 | 0.84 | SIGMAR1 (0.79) | SIGMAR1LMNAPOLBMAPK1CYP1A2 | |
| SCHEMBL10005270 | 0.84 | SIGMAR1 (0.79) | SIGMAR1LMNAPOLBMAPK1CYP1A2 | |
| SCHEMBL3235181 | 0.84 | SIGMAR1 (0.79) | SIGMAR1LMNAPOLBMAPK1CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230038589-A1 | Methods and compositions for targeting Tregs using CCR8 inhibitors | Nanjing Immunophage Biotech Co., Ltd. (CN) | 2023-02-09 | — | — | US | disclosed |
| US-20120041225-A1 | KIT FOR AUTOMATED RESOLVING AGENT SELECTION AND METHOD THEREOF | VAIDYA NITEEN A (US) | 2012-02-16 | — | — | US | disclosed |
| US-20120041225-A1 | KIT FOR AUTOMATED RESOLVING AGENT SELECTION AND METHOD THEREOF | VAIDYA NITEEN A (US) | 2012-02-16 | — | — | US | disclosed |
| US-3994974-A | BRONCHODILATORS | YAMANOUCHI PHARMACEUTICAL CO., LTD. (JA) | 1976-11-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120041225-A1 | KIT FOR AUTOMATED RESOLVING AGENT SELECTION AND METHOD THEREOF | ACKR3, KIT, C3AR1 | SIGMAR1 3129/4885SMN1; SMN2 2706/4885LMNA 981/4885 |
| US-20230038589-A1 | Methods and compositions for targeting Tregs using CCR8 inhibitors | CCR8, CCR1, CCR3 | SIGMAR1 4425/4885SMN1; SMN2 4731/4885LMNA 4214/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.